Two diagnostics companies unveiled plans that accelerate commercial minimal residual disease (MRD) testing: Natera said its Signatera assay delivered record growth in Q4 and will roll out a phased-and-structural-variant-enhanced version in mid‑2026; Veracyte announced a TrueMRD launch in H1 with reimbursement and targeted indications beginning with muscle-invasive bladder cancer. Natera outlined enhancements that integrate phased and structural variants and a multimodal model combining ctDNA, pathology and clinical data to raise MRD sensitivity; the company signaled Medicare reimbursement expectations will improve average selling prices. Veracyte said TrueMRD will launch with payer coverage and separate billing codes for upfront and surveillance testing, and it plans sequencing-based Prosigna breast assays later in the year. Both firms emphasized data-generation programs and payer strategies as central to MRD commercialization: the moves mark an intensifying competition for tumor-informed MRD adoption across oncology channels.